PIH17 A Cost of a Childbirth with in vitro Fertilization in Poland  by Góra, K. et al.
A332  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
Objectives: Rotavirus (RV) is the most frequent cause of severe gastroenteritis fre-
quently requiring hospitalization. RV is responsible for > 1/2 of all hospital stays 
for acute gastroenteritis. The objective was to estimate the burden of community 
acquired rotavirus gastro-enteritis requiring hospitalization (CRVGE) in children ≤ 5 
years old in Czech Republic (CR) and Slovakia (SK). MethOds: Multi-center, retro-
spective patient chart review was conducted in both pediatric and infection disease 
settings in CR (n= 109) and SK (n= 115). Resource use analysis including length of hos-
pital stay and tests performed were evaluated. Patients requiring rehydration, compli-
cations and comorbidities were considered. Direct cost from payer’s perspective were 
retrieved from official DRG lists (CR) and fixed hospitalization cost rates per case (SK). 
Micro-costing was done in parallel based on the resource use data. Results: Mean 
length of hospital stay in CR and SK was 3.9 (SD 1.9) and 4.1 days (SD 1.7) respectively. 
Prevalent diagnostic tests used were latex agglutination 44.0% (CR) and immunochro-
matography 92% (SK). Rehydration was required in 84.4% (CR) and 97% (SK) of cases. 
Comorbidities were reported in 24.8% (CR) and 27% (SK); complications in 10.1% (CR) 
and 7.8% (SK). The national list-based reimbursement per hospitalized CRVGE is € 
370-645 (CR) and € 561 (SK). The calculated average total costs, including treatment 
prior to, and after admission, were € 462 (CR) and € 583 (SK). The major cost item was 
the hospital stay with € 391 (CR) and € 540 (SK). Costs for tests and drugs during hos-
pitalization were € 30 (CR) and € 25 (SK). The costs of pre and post-hospitalization care 
were € 20 (CR) and € 13 (SK). cOnclusiOns: Although the length of hospitalization 
in both countries is similar costs seem to be substantially lower in CR, possibly as a 
result of recently launched DRG system. Common complications and comorbidities 
account for 30% of average hospital costs.
PIH14
Use of AntenAtAl CortICosteroIds lowers HosPItAlIzAtIon Costs 
relAted to PremAtUrIty
Meneguel J.1, Fonseca M.2, Fonseca E.3, Almeida F.1, Grinsburg R.1
1UNIFESP, São Paulo, Brazil, 2Federal University of São Paulo / Axia.Bio Consulting, São Paulo, 
Brazil, 3Federal University of São Paulo, São Paulo, Brazil
Objectives: According to WHO the use of antenatal corticosteroids (CEA) in pregnant 
women at risk of preterm birth < 34 weeks can prevent thousands of preterm neonates 
(PN) deaths. The impact of the use of CEA in hospital costs in developing countries is 
not known. Our objective was to compare morbidity and hospital costs of PN whose 
mothers received or not CEA. MethOds: Analysis of PN medical records with gesta-
tional age 26-32 weeks born from Jan/2006-Dez/2009 in a tertiary, public and university 
hospital. We excluded infants with malformations. Maternal characteristics, hospital 
neonatal morbidity, use and doses of CEA and all used resources (tests, medications 
and procedures) were collected. Costs were estimated in Brazilian Reais, from the 
hospital perspective. Results: Of 211 PN, 170 received at least one dose of CEA to 6 
hours before delivery (G1) and 41 did not (G2). The groups had similar characteristics 
but G1 had more male infants (p < 0.05) and cesarean sections (p < 0,00). Morbidity: 
G2 needed more advanced resuscitation (16.5% vs 34%, p = 0.01), experienced more 
intraventricular hemorrhage III / IV (7.6% vs. 22%, p < 0.00) and retinopathy of pre-
maturity (12.4% vs. 24.4%, p = 0.05). Resource use: G1 consumed less mechanical 
ventilation days (5.3 vs 10.6, p = 0.04) and oxygen days (10.7 vs 17, p = 0.02); the num-
ber of NICU and Intermediate Care Nursery days were respectively (19.6 vs 27.5, p = 
0.07) and (24 vs 29.5 days, p = 0.14); there was no difference concerning use of CPAP 
(p = 0.07) and surfactant (p = 0.06). The average cost of hospitalization per patient 
was BRL 18,409 in G1 and BRL 24,090 in G2 (p = 0.03). cOnclusiOns: The CEA is a 
simple measure, which helps to reduce PN morbidity and utilization of health care 
resources, reducing hospital costs.
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Objectives: To examine the burden of illness of patients diagnosed with 
Alzheimer’s disease (AD) in the U.S. veteran population. MethOds: A retrospective 
database analysis was performed using the Veterans Health Administration (VHA) 
Medical SAS datasets from October 1, 2008 through September 30, 2012. Patients 
diagnosed with AD were identified using International Classification of Disease 9th 
Revision Clinical Modification (ICD-9-CM) diagnosis code 331.0. The first diagnosis 
date was designated as the index date. A comparator group was created as well by 
identifying patients without an AD diagnosis but with the same age, region, gender, 
index year, and matching Charlson Comorbidity Index (CCI). The index date for 
the comparator group was randomly chosen to reduce the selection bias. A 1-year 
continuous health plan enrollment was required before and after the index date 
for both groups. One-to-one propensity score matching was used to compare the 
health care costs and utilizations during the follow-up period between the disease 
and comparator groups. Results: A total of 68,856 patients were included in the 
AD and comparison cohorts. After 1:1 matching, a total of 24,542 of patients were 
matched from each group, and the baseline characteristics were proportionate. The 
AD cohort had higher percentages of inpatient (18.46% vs. 2.06%, p< 0.01), emergency 
room (15.80% vs. 4.31%, p< 0.01), physician office (98.17% vs. 58.18%, p< 0.01), outpa-
tient (98.30% vs. 58.92, p< 0.01), and pharmacy visits (84.89% vs. 61.78%, p< 0.01). AD 
patients also incurred higher inpatient ($7,416 vs. $636, p< 0.01), emergency room 
($150 vs. $41, p< 0.01), physician office ($2,752 vs. $1,155, p< 0.01), outpatient visits 
($3,086 vs. $1,300) and pharmacy costs ($774 vs. $350, p< 0.01) compared to patients 
without AD. cOnclusiOns: In this study, AD was associated with higher health 
care resource utilization and a significantly higher economic burden.
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women with EAPP. A recently cost-minimization (CM) model developed for EAPP 
provided the estimates of average treatment cost in Brazil based on local guidelines. 
This CM model compared different treatment pathways for women with EAPP and 
used a 50% improvement in pelvic pain as a definition of a treatment response. A 
patient flow was developed based on epidemiological and demographical data. 
Based on market uptake assumptions, results from the CM model and the patient 
flow, the BIM estimated the incremental budget impact after adopting dienogest. 
The model assumed that during the first year, 6.76% of EAPP patients receive dien-
ogest in detriment of GnRHa. After five years, it was assumed that dienogest would 
capture 30% of the GnRHa market in EAPP. Results: Based on the patient flow 
developed, approximately 0.52% of the population were estimated to be diagnosed 
with EAPP and receiving treatment with GnRHa. In the year after introduction of 
dienogest, the overall budget used to treat EAPP was estimated to decrease by 
up to 2.98% with the budget saving estimated to increase to around 12.98% by 
Year 5. cOnclusiOns: This analysis portends that the budgetary impact of add-
ing dienogest to the public health care system in Brazil, in detriment of the GnRHa, 
result in a budgetary cost saving alternative.
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Objectives: Second-line pharmacological therapy for benign prostatic hyperplasia 
(BPH) includes 5α -reductase inhibitors (5ARIs, dutasteride and finasteride). Aim of this 
study was the evaluation of the budget impact related to the variation in dutasteride 
and finasteride prescribing trends. MethOds: Target population is the number of 
Italian BPH-patients, age ≥ 40 years, treated with dutasteride or finasteride. The BPH-
patients management was modeled on a dynamic cohort for 4-years. Epidemiological 
input data were elaborated from a observational study on pharmaceutical prescrip-
tion data of Italian BPH-patients; hospitalization rates were taken from a cohort study 
investigating BPH-related surgical and not surgical hospitalizations. Costs were cal-
culated as average of Italian DRGs weighted for BPH-related procedure frequency. 
Current Italian prescription shares of dutasteride and finasteride were compared 
with a 20% shift of prescriptions from dutasteride to finasteride (Scenario A) and 
a 20% shift of prescription from finasteride to dutasteride (Scenario B). Results: 
According to current prescribing trends, 372,078 hospitalizations for BPH are expected 
in 4 years. Mean annual cost for BPH-patients management results in 355 million € . 
Hospitalization cost is the main driver (228 milion € /year) while pharmacological ther-
apy accounts for 35% of the total cost (126 million Euro/year). Scenario A: additional 
11.485 hospitalizations related with BPH occur in 4 years; these lead to an increase in 
NHS cost only slightly offset by the savings in drugs acquisition cost: -0,08% savings 
on NHS budget (-0,28 milion € /year) Scenario B: the cost of drugs increases of 5% (+6 
million € /year) and prevents 9,920 hospitalizations in 4 years; the net budget impact 
of scenario B is +0,08% increase in cost (+0,27 milion € /year). cOnclusiOns: The 
shift of prescription from dutasteride to finasteride leads to modest savings on NHS 
Budget while the shift from finasteride to dutasteride offsets the majority of increase 
in drug budget improving the outcome in patients.
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Objectives: Different types of labour need different resources. Therefore, 
different costs could be expected. Objectives of this study were to determine if sig-
nificant differences in costs of different type of labour and methods of delivery exist 
and to determine factors related to estimated costs. The costs of spontaneous labour 
with vaginal delivery (SVD), induced labour with vaginal delivery (IVD), and planned 
C-section (CS) without labour were estimated. MethOds: Retrospective, population-
based study was conducted for the period January – December, 2010. Health Insurance 
Fund of Republic of Serbia (HIFRS) database was used as a data source. Direct medical 
costs of mother/newborn pair were estimated. Costs were observed from the perspec-
tive of HIFRS and expressed in European Monetary Unit (EUR). Results: A total of 
99 women were selected for the study sample; average age was 30.55±5.42 years. The 
majority of women (46.5%) had SVD, 28.3% had IVD and 25.2% had CS. Women with 
CS were longer hospitalized compared to women with SVD and IVD (8.52±4.74 vs. 
4.59±2.89 and 5.04±3.01 days, respectively, p< 0.05). Newborns after CS were longer hos-
pitalized compared to newborns after SVD and IVD (5.76±2.20 vs. 4.0±2.07 (p< 0.05) and 
5.14±3.39 (p> 0.05)). Majority of women (88.0%) and children (80.0%) after CS were hos-
pitalized at semi-intensive and/or intensive care unites. The average costs of delivery, 
regardless of the method, were 417.02±284.14 EUR. The costs of C-section were higher 
compare to SVD (640.18±240.04 vs. 243.27±131.70 EUR, p< 0.05) and IVD (640.18±240.04 
vs. 497.10±327.91 EUR, p>0.05). cOnclusiOns: The highest costs of labour in Serbia 
were costs of planned CS. Longer maternal/newborns hospital stay and more 
frequent hospitalization at semi-intensive and/or intensive care unites after CS 
were leading factors of estimated high costs. Considering high costs of CS, it is neces-
sary to review such clinical practice for the purpose of optimizing the use of resources.
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Objectives: To establish if the procalcitonin (PCT) test’s diagnostic performance 
is more clinically and cost-effective than C reactive protein (CRP) and White 
Cell Count (WCC) tests for suspicion of prodomal stage Meningococcal disease 
(MD) in children presenting at emergency department (ED) with a fever without 
source. MethOds: A decision analytic model was designed to reflect realistic 
clinical pathways for a child presenting with non-specific fever to ED. Test accu-
racy was evaluated using data from independent studies carried out in developed 
countries identified through a systematic literature search. Studies were combined 
to determine the optimal cut-off value for the PCT, CRP and WCC tests, each as an 
indicator of MD. Summary Receiver Operator Curve (SROC) analysis was used to 
determine the inter-study and overall diagnostic performance of each test from 
the areas under the curve (AUC), with 95% confidence intervals (CIs). Components 
of each clinical pathway were costed in UK sterling using the National Schedule 
of Reference Costs 2010-2011. Hospital stays were costed using the appropriate 
Health Resource Group code. Results: Seven studies involving 881 children with 
non-specific fever provided data for inclusion. The PCT test was more accurate 
(sensitivity= 89%, 95%CI= 75-96; specificity= 71%, 95%CI= 37-91) for early MD com-
pared to CRP (sensitivity= 84%, 95%CI= 74-90; specificity= 60%, 95%CI= 44-74) and 
WCC (sensitivity= 50%, 95%CI= 39-60; specificity= 68%, 95%CI= 54-79). PCT had the 
best PLR (3.0, 95%CI= 1.8-7.8) to be viable as a rule-in test for MD and a borderline 
NLR as a rule-out test, making it a better option to either CRP (2.1, 95%CI= 1.4-3.1) 
or WCC (1.5, 95%CI= 1.0-2.3). Outcomes from the decision analytic model indicated 
that the PCT test was the most cost-effective (£2547 per patient treated), followed 
by the combined CRP and WCC test (£3069 per patient treated). cOnclusiOns: The 
improved sensitivity and specificity of the PCT test provides a more cost-effective 
test than the currently recommended CRP and WCC tests.
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Objectives: To evaluate the cost-effectiveness of first-line treatment of heavy men-
strual Bleeding (HMB) from the perspective of the Spanish National Healthcare 
System. MethOds: A cost-effectiveness analysis was performed using a Markov 
model to simulate the evolution of a cohort of women in reproductive age, with 
HMB and who wish to preserve their fertility status, in a time horizon of 5 years. 
The treatment strategies were levonorgestrel intrauterine system (LNG-IUS), estra-
diol valerate/dienogest (E2V/DNG), combined oral contraceptives (COC) and oral 
progestins (PROG). Clinical data was modelled indirectly combining literature and 
expert opinion. Outcomes were symptom-free months (SFM), quality-adjusted life 
months (QALM) and costs expressed in € in 2012. A probabilistic sensitivity analy-
sis was conducted to examine the robustness of the results. Results: The mean 
treatment cost of HMB at 6 month was 205€ for LNG-IUS, 318€ for E2V/DNG, 412€ 
COC and 766€ PROG. In the analysis over 5 years, LNG-IUS produced savings of 
578€ compared to E2V/DNG, 991€ compared to COC and 1,821€ compared to PROG. 
Regarding the effectiveness, LNG-IUS provided 51.30 SFM, while E2V/DNG, COC and 
PROG provided 50.64, 49.09 and 47.77 SFM, respectively. Moreover, 77%, 65%, 56% and 
46% of the patients treated with LNG-IUS, E2V/DNG, COC and PROG, respectively, 
continued treatment without surgery during the 5 year period. Considering QALM 
as outcome, LNG-IUS and E2V/DNG were the options that yielded more gains in 
QALM (49.71 for LNG-IUS, 48.09 for E2V/DNG, 46.59 for COC and 44.66 for PROG). 
LNG-IUS was the most effective and less costly, therefore dominant option. In the 
oral treatments comparison, E2V/DNG was dominant, providing savings and gains in 
terms of SFM and QALM. The probabilistic sensitivity analysis on the key parameters 
confirmed the robustness of the base case. cOnclusiOns: LNG-IUS is a cost-saving 
option for the treatment of HMB in Spain. Among oral treatments, E2V/DNG is also 
a dominant strategy.
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Objectives: Brazil is among the countries with the highest incidence of preterm 
births. Incorporation of diagnostic tests to predict a preterm birth could improve 
the efficiency of the clinical practice reducing hospital expenses related to mater-
nal hospitalization. The aim of this study was to compare the cost-effectiveness 
of fibronectin testing (FN) vs cervical length (CL) measurement in women with 
symptomatic preterm labor. MethOds: Systematic review of the literature of the 
diagnostic tests and development of a decision analytic model using the accuracy of 
the diagnostic tests to predict preterm birth and project the results in terms of effec-
tiveness and cost. The analysis was performed for a hypothetical cohort of 10,000 
patients, for each test, with symptomatic preterm labor between 24 and 34 weeks of 
gestation. The primary perspective of the study was of the Brazilian Health system 
(SUS). Data sources were the medical literature, SUS official published prices for 
medicines and DATASUS (SUS database). Costs are in 2012 Brazilian Reais. Results: 
A total of 14 studies were included. There was a wide variation concerning the accu-
racy of the tests among the studies, particularly with respect to gestational age at 
Objectives: To predict the cost of a delivery following assisted reproductive 
technologies (ART) in Poland. Moreover, the cumulated in vitro fertilization (IVF) 
effectiveness ratio was calculated and the costs of drugs for each of the three 
stimulation protocols used in IVF (long with GnRH agonist, short with GnRH 
antagonist and short with GnRH agonist) were estimated. MethOds: In order to 
calculate the IVF effectiveness, a pooled analysis of the results from European IVF 
monitoring reports concerning Poland from 2008 to 2010 was performed. Costs of 
the clinical and biotechnological parts of IVF were based on the Ministry of Health 
calculation. Drugs’ costs were estimated considering both dosages based on the 
Summaries of Products Characteristics and the retail prices. Costs were calculated 
based on identified costs in both the patient and payer perspectives. Results: 
The overall birth rate per cycle was 21,70%. The probability of a delivery was 
1,5 higher during fresh cycle than in frozen embryo transfer. A total of 24,09% 
of embryo transfers resulted in delivery. The cost of drugs used during ovarian 
stimulation protocol was estimated on 6 055 PLN. The average cost per cycle was 13 
565 PLN. Drugs account for 45% of this value. The average cost per birth was 42 848 
PLN. cOnclusiOns: In vitro fertilization is an expensive procedure for a patient 
in Poland. It is due to a limited effectiveness, usually requiring several repeats of 
the whole cycle of IVF with no drugs reimbursement. The ovarian stimulation is 
the most expensive part of the procedure. Thus, reimbursement of medication 
should also be established.
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Objectives: Toxoplasma infection during pregnancy presents a serious hazard 
to the fetus including lifelong disabilities of connatal infected children. This 
foodborne illness is a common burden worldwide. Prevention strategies of the 
health care providers are diverse. In Austria, the maternal toxoplasma screening 
has been implemented four decades ago. The aim of this study was to deter-
mine cost-effectiveness of the maternal toxoplasma screening. MethOds: We 
developed a two arm decision-analytic model. One arm of the model assessed 
the costs and consequences of no prevention, while the other one evaluated 
the screening. The study population included pregnant women and offspring 
screened and treated for toxoplasma infection. The average number of births 
was 76,547 and 50,000 pregnant women were susceptible to infection. The 
analysis focused on lifetime consequences of the connatal infection. This 
encompassed direct costs (screening, cost of illness, maternal and pediatric 
treatment), indirect costs (changed job situation of parents, human-capital of 
dead individuals, blindness and special schools), quality-adjusted-life-years 
(QALYs) and reduced expectation of life. Costs were presented per child and 
for the Austrian birth cohort. Costs from published sources were used (2012 
Euro) from the societal perspective. QALYs, life-years (LYs) and costs were pro-
jected over a life-time horizon and discounted at 3% p.a. Results: Maternal 
toxoplasma screening reduced transmission risk by 40% and one quarter of 
affected children showed symptoms. We found five-times higher lifetime costs 
per child without prevention compared to screening. Also direct costs were 
lower in the latter group; screening costs did not offset costs of sequelae. A split 
in direct and indirect costs components demonstrated that proportion of direct 
costs without prevention amounted to 20% and 95% with screening. Screening 
resulted in QALYs gained and LYs saved. cOnclusiOns: Funding the maternal 
toxoplasma screening saves money and is cost-effective for the society and the 
Austrian health care system.
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Objectives: Rotavirus gastroenteritis is a major health burden in young chil-
dren worldwide. This study investigates the cost-effectiveness of universal pae-
diatric rotavirus vaccination with RIX4414, a two-dose human rotavirus vaccine, 
in Greece. MethOds: A Markov cohort model with a cycle time of one month 
was constructed in Microsoft Excel. The birth cohort of 114,766 infants, based 
on 2010 official registry was entered into the model and followed over average 
life expectancy with acute rotavirus events measured up to five years of age. 
Probabilities, utility scores and costs for hospitalisations, hospital-acquired 
rotavirus infection, medical consultations, emergency visits and deaths due to 
rotavirus were taken from published sources and national databases. Costs and 
benefits were reported at 2012 euros, discounted at 3% and 1.5% respectively 
per year and compared between a vaccinated and unvaccinated cohort from 
a Social Sick-Fund perspective. Results: Vaccination with RIX4414 incurred 
an incremental cost of € 16,569 per QALY at a price of € 48/dose. The estimated 
number of rotavirus-related diarrhoea events per year up to the age of five is 
45,906. Total direct medical cost of rotavirus disease without vaccination is 
around € 8,980,000 per year in Greece. Vaccination (40% coverage) reduces the 
number of gastro-enteritis events by 27% to 33,492 and the number of rotavirus-
related medical visits from 17,214 per year to less than 11,000. Total cost of 
rotavirus disease, including the costs of vaccination, in the vaccinated cohort 
is estimated at € 10,087,614 per year, with a cost reduction on direct medical 
costs of € 3,343,781. This cost reduction reflects the high financial disease burden 
related to the medical visits including paediatricians, emergency and hospital 
visits. cOnclusiOns: Paediatric vaccination against rotavirus with RIX4414 
versus no vaccination in Greece improves health outcomes, reduces direct medi-
cal costs and is cost-effective from a social sick fund perspective.
